Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01375842
Title A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Atezolizumab

Age Groups: adult
Covered Countries USA | FRA | ESP


No variant requirements are available.